211 results on '"Gelmon KA"'
Search Results
2. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
3. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2
4. Abstract P4-08-03: Looking forward to the TNM 9th edition: Is it time to stage the different breast cancer subtypes as distinct diseases?
5. Abstract P4-08-27: The 21-gene Recurrence® (RS) Score assay in estrogen receptor positive node negative breast cancer: Real-world chemotherapy usage and patient characteristics within the intermediate and high-risk RS category
6. Abstract P1-13-02: Real world outcomes of adjuvant FECD, ddACT and ACT for the treatment of early stage breast cancer - A multicenter retrospective analysis
7. Abstract P3-08-13: Exploring the role of ctDNA in triple negative breast cancer
8. Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial
9. Abstract P4-08-01: Is the 8th edition of the breast cancer TNM staging system an improvement over the 7th edition?
10. Abstract P5-21-25: Efficacy and safety of palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2
11. Abstract P5-19-01: Impact of palbociclib plus letrozole on patient-reported general health status compared with letrozole alone in ER+/HER2- advanced/metastatic breast cancer
12. Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups
13. Abstract P6-07-06: Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31
14. Abstract P5-12-10: Comparison of the efficacy of tamoxifen and aromatase inhibitors on survival in adjuvant menopausal breast cancer
15. Abstract P3-12-05: The BC provincial experience on FEC-D vs. AC-taxane protocol as adjuvant treatment for breast cancer
16. P1-06-08: Effect of Treatment Emergent Symptoms on Relapse Free Survival: NCIC CTG MA.12 a Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women in Early Breast Cancer.
17. P1-12-25: Evaluation of PTEN, EGFR and Ki67 Expression as Predictors of Response to a Trastuzumab-Containing Neoadjuvant Chemotherapy Regimen in a HER-2 Over-Expressing Locally Advanced Breast Cancer (LABC) Trial.
18. P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis.
19. P2-14-02: NCIC CTG MA.27: Clinical Tolerability and Overall Survival of Racial and Ethnic Minority Women on Aromatase Inhibitor Therapy.
20. Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials.
21. A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes.
22. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
23. Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole.
24. Cancer treatment-induced bone loss in breast and prostate cancer.
25. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials.
26. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
27. Resting energy expenditure and body mass changes in women during adjuvant chemotherapy for breast cancer.
28. Trastuzumab-associated peripheral vascular toxicity.
29. Lymph-node-negative oestrogen-receptor-positive breast cancer.
30. The mammography screening debate: time to move on.
31. The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities
32. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
33. Understanding breast cancer patients' preference for two types of exercise training during chemotherapy in an unblinded randomized controlled trial
34. Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials.
35. Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.
36. Improving Care for Older Adults with Cancer in Canada: A Call to Action.
37. Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review.
38. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
39. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
40. Can we successfully define and target BRCA-like breast cancers?
41. Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape.
42. Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
43. Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
44. Reply to Y. Wang et al and Q. Sui et al.
45. Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32).
46. Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891-9895".
47. Prognostic Tests in Early-Stage Hormone Receptor-Positive Breast Cancer: An Opportunity to Refine Personalized Cancer Care.
48. A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
49. Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
50. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.